Abstract:Background Frontotemporal lobar degeneration (FTLD) is second only to Alzheimer’s disease as a cause of dementia, and we find the scaffolding protein β‐arrestin2 is elevated in human brains with this condition, and is responsible for accumulation of pathological tau tangles. Increased β‐arrestin2 impairs tau clearance and promotes tau aggregation by impeding the autophagy cargo carrier p62/SQSTM1. Such activity requires β‐arrestin2 in its oligomeric form, an assembly state that is not involved with receptor binding. Virus delivered gene therapy to the brain with dominant‐negative mutant β‐arrestin2s ablates pathologic tau in neurons of a mouse model of FTLD‐tau, revealing a new strategy to mitigate tauopathy by targeting β‐arrestin2 oligomerization. Method mice: Arrb2 − / − , tau P301S, and WT mice were all bred in the C57BL6 background. Patients samples: Frozen frontal cortex tissue samples were obtained from the Alzheimer’s Disease Research Center at Emory University. We used samples from FTLD‐tau diagnosed patients. Primary neuronal cultures, Proximity ligation assay (PLA), Immunocytochemistry and Immunohistochemistry, Sarkosyl extraction, Generation of rAAV9 and stereotaxic injections, Electrophysiology, and Atomic force Microscopy Imaging applications were used in this study. Result β‐arrestin2 levels in brains of FTLD‐tau patients and tau P301S transgenic mice were significantly increased. β‐arrestin2 increases tau stability without altering tau mRNA levels. Furthermore, genetic reduction of β‐arrestin2 mitigates tauopathy and synaptic dysfunction in tau P301S mice. β‐arrestin2 oligomerization is required for tau stability, and β‐arrestin2 oligomers increase tau levels by inhibiting self‐association of the autophagy cargo receptor p62/SQSTM1, impeding p62 autophagy flux. Hence, reduction of oligomerized β‐arrestin2 with virus encoding β‐arrestin2 mutants acting as dominant‐negatives markedly reduced tau‐laden neurofibrillary tangles in FTLD mice in vivo . Reducing β‐arrestin2 oligomeric status represents a new strategy to alleviate tau pathology in FTLD and related tauopathies. Conclusion Based on our findings, the effects of inhibiting β‐arrestin2 oligomerization would be expected to not only inhibit the development of new tau tangles, but also to clear existing tau accumulations due to this mechanism of enhancing tau clearance. Beyond tauopathy, it is conceivable that this strategy could also prove to be beneficial in other neurodegenerative diseases bearing proteinopathies that are cleared via p62.

Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation

Specific binding of Hsp27 and phosphorylated Tau mitigates abnormal Tau aggregation-induced pathology

RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction

G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10

Axon guidance genes are regulated by TDP-43 and RGNEF through long-intron removal

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

RNA G-quadruplexes and calcium ions synergistically induce Tau phase transition

Aggregation of the Nucleic Acid–binding Protein TDP-43 Occurs Via Distinct Routes That Are Coordinated with Stress Granule Formation

Manipulating TDP43 Aggregation via RNA G-quadruplexes

Enhanced Tau Pathology Via RanBP9 and Hsp90/Hsc70 Chaperone Complexes

Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase

BAG3 Regulation of Rab35 Mediates the Endosomal Sorting Complexes Required for Transport /endolysosome Pathway and Tau Clearance

β‐arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates: Molecular and cell biology: Tau‐related mechanisms

Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: A vicious cycle in Alzheimer neurodegeneration

BAG3 regulates RAB35 mediates the Endosomal Sorting Complexes Required for Transport/Endolysosome pathway and Tau clearance

Cell redistribution of G quadruplex‐structured DNA is associated with morphological changes of nuclei and nucleoli in neurons during tau pathology progression

Tau Accumulation via Reduced BAG3-mediated Autophagy Is Required for GGGGCC Repeat Expansion-Induced Neurodegeneration

14-3-3 binding regulates Tau assembly and microtubule association

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

Axonal Tau sorting depends on the PRR2 domain and 0N4R-specific interactions hint at distinct roles of Tau isoforms in synaptic plasticity

Modulation of RNA-dependent Interactions in Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD